-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On April 16, Chengdu Pilot issued an announcement that the company's clinical trial application for the company's innovative drug HG381 for injection has obtained the default approval of the State Food and Drug Administration, and plans to conduct clinical research on the treatment of advanced solid tumors.
The human body's innate immune system recognizes molecules in pathogenic microorganisms through pattern recognition receptors (PRR) and triggers an immune activation response.
HG381 is a new molecular entity independently developed by Chengdu Lead based on DNA-encoded compound library technology and small molecule new drug research and development platform.
At present, several innovative drugs based on this mechanism are in the early stage of clinical trials in the world.
Source: Chengdu Pilot's official website
Novartis’ ADU-S100 obtained from Aduro and Merck’s MK-1454 are both small molecule cyclic dinucleotide (cGAMP) natural ligand derivatives.
Among domestic companies, the STING agonist IMSA101 developed by Jiahe Biological has already carried out Phase I clinical trials abroad.